

## Risk factors for septic shock in acute obstructive pyelonephritis requiring emergency drainage of the upper urinary tract

Jun Kamei · Hiroaki Nishimatsu · Tohru Nakagawa ·  
Motofumi Suzuki · Tetsuya Fujimura · Hiroshi Fukuhara ·  
Yasuhiko Igawa · Haruki Kume · Yukio Homma

Received: 5 July 2013 / Accepted: 16 August 2013  
© Springer Science+Business Media Dordrecht 2013

### Abstract

**Purpose** To assess the risk factors for septic shock in patients with acute obstructive pyelonephritis requiring emergency drainage of the upper urinary tract.

**Methods** We retrospectively reviewed the records of 48 patients who underwent emergency drainage of the upper urinary tract for sepsis associated with acute obstructive pyelonephritis at our institute. Univariate and multivariate analyses were performed to identify the risk factors.

**Results** Among 54 events of sepsis, we identified 20 events of septic shock requiring vasopressor therapy. Cases with shock were more likely than those without shock to have ureteral stone (70 vs 38 %,  $p = 0.024$ ) and positive blood culture results (81 vs 28 %,  $p = 0.006$ ). They received drainage significantly earlier than those without shock (1.0 vs 3.5 days,  $p < 0.001$ ). Univariate analysis demonstrated that acute obstructive pyelonephritis by ureteral stone, rapid progression (the occurrence of symptoms to drainage  $\leq 1$  day), positive blood culture, leukocytopenia ( $< 4,000/\text{mm}^3$ ), thrombocytopenia ( $< 120,000/\text{mm}^3$ ), and prothrombin time international normalized ratio  $\geq 1.20$  were correlated with septic shock. Multivariate logistic regression analysis identified thrombocytopenia

( $p = 0.005$ ) and positive blood culture ( $p = 0.040$ ) as independent risk factors for septic shock.

**Conclusions** Thrombocytopenia and positive blood culture were independent risk factors for septic shock in acute obstructive pyelonephritis requiring emergency drainage. Thrombocytopenia would be practically useful as a predictor of septic shock.

**Keywords** Acute obstructive pyelonephritis · Septic shock · Thrombocytopenia · Ureteral drainage

### Introduction

Acute obstructive pyelonephritis sometimes requires emergency drainages of the upper urinary tract by percutaneous nephrostomy or retrograde ureteral stenting [1]; however, septic shock may develop despite appropriate emergency drainage.

The Surviving Sepsis Campaign Guidelines, first published in 2004 and updated in 2008 [2, 3], are now regarded as the international standard for treatment of severe sepsis including urosepsis. Although the guidelines recommend emergency drainage for acute obstructive pyelonephritis, little information is known for the risk for developing septic shock in spite of drainage. Recently, Yamamoto et al. reported that age and presence of paralysis were independent risk factors for septic shock in patients receiving emergency drainage for acute pyelonephritis with ureteral calculi. However, in this study, they analyzed limited cases only with ureteral calculi [4], and for cases with other causes, the risk factor remains uncertain. Thus, in this study, we have attempted to identify the risk factors for septic shock in cases with other causes as well as ureteral calculi.

---

J. Kamei · H. Nishimatsu · T. Nakagawa · M. Suzuki ·  
T. Fujimura · H. Fukuhara · H. Kume (✉) · Y. Homma  
Department of Urology, The University of Tokyo Hospital,  
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  
e-mail: KUMEH-URO@h.u-tokyo.ac.jp

Y. Igawa  
Department of Continence Medicine, Graduate School of  
Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,  
Tokyo 113-8655, Japan

## Methods

We retrospectively reviewed the records of patients who underwent emergency drainage of the upper urinary tract for sepsis associated with acute obstructive pyelonephritis at our institute from April 2006 to September 2011. The diagnosis of sepsis was made by the criteria for systemic inflammatory response syndrome (SIRS), which included two or more of the following conditions: (1) body temperature greater than 38 °C or less than 36 °C, (2) heart rate greater than 90 beats per minute, (3) tachypnea, as manifested by a respiratory rate greater than 20 breaths per minute or hyperventilation, as indicated by a partial CO<sub>2</sub> pressure less than 32 mmHg, and (4) white blood cell count greater than 12,000/mm<sup>3</sup> or less than 4,000/mm<sup>3</sup>, or more than 10 % immature neutrophils [5, 6]. Patients' age, sex, underlying comorbidities, performance status, the side of infected kidney, type of drainage, cause of obstruction, and the time interval between the occurrence of symptoms of pyelonephritis and drainage were recorded. We also evaluated SIRS score, the results of blood and urine culture before antibiotic treatment, and laboratory examinations including blood leukocyte count, blood thrombocyte count at nadir, C-reactive protein (CRP), serum creatinine and total bilirubin level, and prothrombin time international normalized ratio (PT-INR) prior to drainage.

Septic shock was defined as sepsis with a systolic blood pressure less than 90 mmHg despite adequate fluid replacement or using vasopressors for at least 1 h [7, 8]. By comparing patients who did or did not progress to septic shock, we identified risk factors for septic shock.

Chi-square test, Student's *t* test, and Mann–Whitney *U* test were used for univariate analysis to compare variables between cases with septic shock and without. All variables that were significant on univariate analysis were entered into multivariate analysis, and logistic regression analysis was used for multivariate analysis. Analyses were performed by JMP 9 (SAS institute Inc., Tokyo, Japan). *P* values less than 0.05 were considered significant. This study was approved by the institutional ethical committee (3,124).

## Results

We identified 48 patients who met SIRS criteria and required emergency ureteral drainage for acute obstructive pyelonephritis. A total of 54 emergency drainage procedures were undertaken, with once in 44, twice in two, and three times in two patients. The patients' clinical characteristics are shown in Table 1. The cause of obstruction was ureteral stone in 27, malignant neoplasm in 14, obstruction of ureteral stent in six, anastomotic stenosis of

ileal conduit in three, adhesion after lower abdominal operation in two, ureteropelvic obstruction in one, and unknown in one. The patients' laboratory data prior to drainage is shown in Table 2. Culture samples prior to treatment were taken from blood and urine in 34 events (63 %) and 53 events (99 %), respectively. Organisms isolated from blood and/or urine culture were *Escherichia coli* (*n* = 22), *Pseudomonas aeruginosa* (*n* = 5), and other gram-negative bacilli (*n* = 12).

Septic shock occurred in 20 events of drainage. No patients without septic shock died, but one female 74-year-old patient died of septic shock in 8 days after drainage. She had end-stage bladder cancer and poor performance status but no other complications. The other 19 cases with septic shock finally recovered from septic shock with intensive care and the median length of hospital stay was 15 days (5–75). Patients with septic shock were treated with antibiotics, vasopressors in all cases, blood infusion in 10 cases, gamma globulin in 10 cases, antithrombin III agents in 6 cases, blood purification therapy in 4 cases, and recombinant human soluble thrombomodulin in 3 cases (Table 3).

Cases with shock were more likely than those without shock to have ureteral stone (*p* = 0.024) and positive blood culture results (*p* = 0.006). They received emergency drainage significantly earlier than those without shock (*p* < 0.001).

Univariate analysis demonstrated that septic shock was significantly associated with ureteral stone (*p* = 0.024), rapid progression (the occurrence of symptoms to drainage ≤ 1 day, *p* = 0.01), positive blood culture (*p* = 0.006), leukocytopenia (<4,000/mm<sup>3</sup>) (*p* = 0.01), thrombocytopenia (<120,000/mm<sup>3</sup>) (*p* < 0.001), and coagulopathy (PT-INR ≥ 1.20) prior to drainage (*p* = 0.004). Multivariate logistic regression analysis identified thrombocytopenia [odds ratio (OR) 23.90; 95 % CI 2.64–216.18; *p* = 0.005] and positive blood culture [OR 9.11; 95 % CI 1.11–74.79; *p* = 0.040] as independent risk factors for septic shock.

## Discussion

We have found that thrombocytopenia and positive blood culture were significantly associated with septic shock independently in acute obstructive pyelonephritis requiring emergency ureteral drainage.

Previous studies documented coagulopathy and thrombocytopenia as the predictors of progression of sepsis [9, 10]. This would be natural in considering the process of multiple organ dysfunction and septic shock [9–11]. Septic conditions stimulate the release of local and systemic proinflammatory mediators, which would result in low systemic vascular resistance and hypotension [12, 13].

**Table 1** Characteristics of patients

	Septic shock (+) (n = 20)	Septic shock (-) (n = 34)	p value
Sex			
Male	5	11	0.568 <sup>†</sup>
Female	15	23	
Age			
Mean (range)	60 (40–81) <sup>a</sup>	64 (38–84) <sup>a</sup>	0.200 <sup>†</sup>
Underlying comorbidities			
Diabetes mellitus	5	10	0.972 <sup>†</sup>
Malignancy	5	16	0.188 <sup>†</sup>
Steroid use	3	7	0.883 <sup>†</sup>
Laterality			
Right	12	19	0.768 <sup>†</sup>
Left	8	15	
Performance status			
0	13	20	0.157 <sup>†</sup>
1	4	8	
2	1	6	
3	2	0	
Drainage			
Percutaneous nephrostomy	5	15	0.160 <sup>†</sup>
Retrograde ureteral stent	15	19	
Cause of obstruction			
Urinary stone	14	13	0.024 <sup>†</sup>
Others	6	21	
SIRS score			
2	4	11	0.388 <sup>†</sup>
3	8	15	
4	8	8	
Interval between onset and drainage (days)			
Median (range)	1.0 (0–3) <sup>b</sup>	3.5 (0–20) <sup>b</sup>	<0.001 <sup>  </sup>
≤1 day	13	7	0.001 <sup>†</sup>
≥2 days	7	27	

<sup>a</sup> Mean (range), <sup>†</sup> chi-square test, <sup>‡</sup> Student's *t* test, <sup>b</sup> Median (range), <sup>||</sup> Mann–Whitney *U* test

These mediators also activate coagulation cascade and promote fibrin clot formation and platelet activation, inducing coagulopathy and thrombocytopenia [12–14]. Our univariate analysis also demonstrated that thrombocytopenia and prolonged PT-INR were risk factors, although the latter did not remain as a significant factor in multivariate analysis. Thrombocytopenia may be clinically useful as a predictor of septic shock, since blood platelet count is a quick test.

Positive blood culture was marginally associated with septic shock in our study. Hsu et al. [15] reported that patients with complicated acute pyelonephritis with positive blood culture were likely to present severe sepsis or shock. However, the results of blood culture need at least 8 h, which may weaken the utility of blood culture in emergency situation [16, 17]. Moreover, in our study, blood culture was not taken correctly in 20 patients; in 14

cases, antibiotic therapy had been already begun before the referral to our institute, which might lead potential selection bias because these cases might have been under serious condition.

Yamamoto et al. reported that the interval from the occurrence of symptoms to drainage was significantly shorter in patients with septic shock in univariate analysis [14], which is similar to our results. Thus, the rapid progression may be an important risk factor but multivariate analysis in our study failed to show the significance.

Serum creatinine and bilirubin were not significant factors in our study, although they are included in the sequential organ failure assessment score [18], which was commonly used to evaluate the organ damage or predict outcomes in septic patients [18, 19]. This may be because serum creatinine level in patients with acute obstructive pyelonephritis, sometimes elevated by obstructive uropathy

**Table 2** Laboratory data of patients prior to drainage

	Septic shock (+) ( <i>n</i> = 20)	Septic shock (-) ( <i>n</i> = 34)	<i>p</i> value
White blood cell count (/μL)	11,200 (1,200–47,900) <sup>a</sup>	11,650 (4,000–35,200) <sup>a</sup>	<0.001 <sup>†</sup>
Leukocytopenia (<4,000/μL %)	5	0	0.01 <sup>‡</sup>
Thrombocyte count nadir (×10,000/μL)	8.15 (0.80–41.90) <sup>a</sup>	22.0 (6.6–54.9) <sup>a</sup>	<0.001 <sup>†</sup>
Thrombocytopenia (<1.2 × 10 <sup>5</sup> /μL %)	16	3	<0.001 <sup>‡</sup>
PT-INR	1.31 (0.92–3.51) <sup>a</sup>	1.13 (0.90–1.49) <sup>a</sup>	0.005 <sup>†</sup>
Elongation of PT-INR (≥1.20 %)	16	12	0.004 <sup>‡</sup>
CRP (mg/dL)	13.69 (4.33–29.74) <sup>a</sup>	12.84 (0.88–37.68) <sup>a</sup>	0.425 <sup>†</sup>
Serum creatinine level (mg/dL)	2.26 (0.93–6.50) <sup>a</sup>	2.13 (0.45–19.79) <sup>a</sup>	0.802 <sup>†</sup>
Serum total bilirubin level (mg/dL)	0.80 (0.20–1.70) <sup>a</sup>	0.60 (0.20–2.40) <sup>a</sup>	0.914 <sup>†</sup>
Blood culture			
Positive	13	5	0.006 <sup>‡</sup>
Negative	3	13	
Urine culture			
Positive	19	23	0.064 <sup>‡</sup>
Negative	1	10	

<sup>a</sup> Median (range), <sup>†</sup> Mann–Whitney *U* test, <sup>‡</sup> chi-square test

**Table 3** Risk factors for septic shock

Variables	Number	Multivariate analysis	
		OR (95 %CI)	<i>p</i> value
Cause of obstruction			
Ureteral stone	27	Reference	0.951
Other	27	1.81 (0.13–23.75)	
Blood culture			
Positive	16	Reference	0.040
Negative	18	9.11 (1.11–74.79)	
Leukocytopenia (<4,000/μL)			
No	49	Reference	0.999
Yes	5	>50 (0.00 to >200.0)	
Thrombocytopenia (<1.2 × 10 <sup>5</sup> /μL)			
No	35	Reference	0.005
Yes	19	23.90 (2.64–216.18)	
PT-INR			
<1.20	26	Reference	0.266
≥1.20	28	3.24 (0.41–25.75)	
Onset to drainage			
≥2 days	34	3.25 (0.37–28.65)	0.288
≤1 day	20	Reference	

rather than SIRS, may not reflect the severity of sepsis. Serum bilirubin level was elevated in only 5 patients with shock in our study.

Comorbidities such as malignancy, diabetes mellitus, and steroid use were known to be associated with infectious diseases [20], although they were not necessarily risk

factors for septic shock in acute obstructive pyelonephritis. Yoshimura et al. [21] reported that diabetes mellitus and immune suppression status were not associated with septic shock by examining 473 patients with urosepsis associated with upper urinary tract calculi. Similarly, Lee et al. [22] found that diabetes mellitus and malignancy were not

related to septic shock in 208 bacteremic acute pyelonephritis patients. However, the reason for the lack of association was not discussed in these papers.

The weakness of our study is a retrospective analysis of a single institution with a limited number of cases. Confirmatory studies with a larger population may be required.

## Conclusion

Our study revealed thrombocytopenia would be clinically more useful as a predictor of septic shock in the emergency room.

**Conflict of interest** None declared.

## References

- Danuser H, Ackermann DK, Studer UE (1993) Urological emergencies. *Schweiz Med Wochenschr* 123:749–755
- Dellinger RP, Carlet JM, Masur H et al (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 32:858–873
- Dellinger RP, Levy MM, Carlet JM et al (2008) International surviving sepsis campaign guidelines committee. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 36:296–327
- Yamamoto Y, Fujita K, Nakazawa S et al (2012) Clinical characteristics and risk factors for septic shock in patients receiving emergency drainage for acute pyelonephritis with upper urinary tract calculi. *BMC Urol* 12:4
- Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 101:1644–1655
- Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. *Intensive Care Med* 29:530–538
- Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. *N Engl J Med* 358:111–124
- Annane D, S ebille V, Charpentier C et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 288:862–871
- Ogura H, Gando S, Iba T et al (2007) SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. *Shock* 28:411–417
- Iba T, Gando S, Murata A et al (2007) Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. *J Trauma* 63:1093–1098
- Amaral A, Opal SM, Vincent JL (2004) Coagulation in sepsis. *Intensive Care Med* 30:1032–1040
- Fitch SJ, Gossage JR (2002) Optimal management of septic shock. *Postgrad Med* 111:53–56
- Court O, Kumar A, Parrillo JE et al (2002) Clinical review: myocardial depression in sepsis and septic shock. *Crit Care* 6:500–508
- Levi M, Cate HT (1999) Disseminated intravascular coagulation. *N Engl J Med* 341:586–592
- Hsu CY, Fang HC, Chou KJ et al (2006) The clinical impact of bacteremia in complicated acute pyelonephritis. *Am J Med Sci* 332:175–180
- Mart nez JA, Pozo L, Almela M et al (2007) Microbial and clinical determinants of time-to-positivity in patients with bacteraemia. *Clin Microbiol Infect* 13:709–716
- van Nieuwkoop C, Bonten TN, van't Wout JW et al (2010) Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. *Crit Care* 14:R206
- Vincent JL, Moreno R, Takala J et al (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 22:707–710
- Jones AE, Trzeciak S, Kline JA (2009) The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. *Crit Care Med* 37:1649–1654
- Lin JN, Tsai YS, Lai CH et al (2009) Risk factors for mortality of bacteremic patients in the emergency department. *Acad Emerg Med* 16:749–755
- Yoshimura K, Utsunomiya N, Ichioka K, Ueda N, Matsui Y, Terai A (2005) Emergency drainage for urosepsis associated with upper urinary tract calculi. *J Urol* 173:458–462
- Lee JH, Lee YM, Cho JH (2012) Risk factors of septic shock in bacteremic acute pyelonephritis patients admitted to an ER. *J Infect Chemother* 18:130–133

## Adrenomedullin and Angiotensin-1 Additively Restore Erectile Function in Diabetic Rats: Comparison with the Combination Therapy of Vascular Endothelial Growth Factor and Angiotensin-1

Hiroaki Nishimatsu, MD, PhD,\* Etsu Suzuki, MD, PhD,<sup>†</sup> Akira Nomiya, MD,\* Aya Niimi, MD,\* Motofumi Suzuki, MD, PhD,\* Tetsuya Fujimura, MD, PhD,\* Hiroshi Fukuhara, MD, PhD,\* and Yukio Homma, MD, PhD\*

\*The Department of Urology, Faculty of Medicine, University of Tokyo, Tokyo, Japan; <sup>†</sup>Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan

DOI: 10.1111/jsm.12177

### ABSTRACT

**Introduction.** Erectile dysfunction (ED) is a major health problem. We have shown that adrenomedullin (AM) restores erectile function in diabetic rats.

**Aim.** The aim of this study is to explore a better treatment for ED, we examined whether combination of AM and angiotensin-1 (Ang-1) was more effective to treat ED than treatment with AM alone or Ang-1 alone. We also compared the effect of the combination therapy with that of treatment with vascular endothelial growth factor-A (VEGF-A).

**Methods.** Male Wistar rats were injected with streptozotocin (STZ) to induce diabetes. Adenoviruses expressing AM (AdAM), Ang-1 (AdAng-1), and VEGF-A (AdVEGF-A) were injected into the penis 6 weeks after STZ administration. Erectile function, penile histology, and protein expression were analyzed 4 weeks after the injection of the adenoviruses.

**Main Outcome Measures.** Intracavernous pressure and mean arterial pressure were measured to evaluate erectile function. The morphology of the penis was analyzed by Elastica van Gieson stain and immunohistochemistry. The expression of  $\alpha$ -smooth muscle actin (SMA), VE-cadherin and type I collagen was assessed by Western blot analysis.

**Results.** Infection with AdAM plus AdAng-1 more effectively restored erectile function than infection with AdAM alone or AdAng-1 alone. This combination therapy restored erectile function to a level similar to that observed in the age-matched Wistar rats. Expression of SMA and VE-cadherin increased more significantly in the AdAM plus AdAng-1-treated group than in the AdAM- or AdAng-1-treated group. Although AdVEGF-A infection restored erectile function significantly, it also caused enlargement of the trabeculae of the cavernous body, aberrant angiogenesis, and overproduction of type I collagen.

**Conclusions.** These results suggested that combination therapy with AM and Ang-1 potentially restored erectile function and normal morphology of the cavernous body compared with VEGF-A administration. This combination therapy will be useful to treat ED patients with a severely damaged cavernous body. **Nishimatsu H, Suzuki E, Nomiya A, Niimi A, Suzuki M, Fujimura T, Fukuhara H, and Homma Y. Adrenomedullin and angiotensin-1 additively restore erectile function in diabetic rats: Comparison with the combination therapy of vascular endothelial growth factor and angiotensin-1. J Sex Med 2013;10:1707–1719.**

**Key Words.** Erectile Dysfunction; Adrenomedullin; Angiotensin-1; Vascular Endothelial Growth Factor; Diabetes And Erectile Function

Hiroaki Nishimatsu and Etsu Suzuki contributed equally to this work.

## Introduction

Erectile dysfunction (ED) is a major health problem that affects more than 10 million of the Japanese male population. It is estimated to affect approximately 75% of male patients with diabetes [1]. Although selective phosphodiesterase type 5 inhibitors (PDE-5) are widely used to treat ED, PDE-5 are less effective in patients with diabetes [2,3], probably because the cavernous body is severely damaged in these patients. To treat ED in the elderly population and in patients with diabetes whose cavernous body is profoundly damaged, it is necessary to explore a novel method to regenerate the cavernous body.

We have shown that administration of adipose tissue-derived stem cells (ASC), which are stem cells derived from subcutaneous adipose tissue, regenerated the cavernous body and restored erectile function in diabetic rats [4]. We have also demonstrated that ASC regenerated the cavernous body by secreting cytokines that stimulate angiogenesis rather than by being integrated in the cavernous body. Furthermore, we have shown that adrenomedullin (AM), a vasoactive peptide that has potent natriuretic, vasorelaxant, and proangiogenic activities [5–8], was produced by ASC and mediated ASC-induced restoration of erectile function [4]. Although AM was effective in restoring erectile function, its effect was apparently weaker than that of ASC administration [4]. It is therefore easily speculated that the combination of several cytokines that ASC produce will further improve erectile function. During the screening of cytokines that ASC produce, we found that angiopoietin-1 (Ang-1) was produced especially when ASC were cultured in medium that contains growth factors for vascular endothelial cells (VECs) [9]. Due to the fact that Ang-1 is also a potent proangiogenic factor [10], it is tempting to speculate that AM and Ang-1 will cooperatively stimulate the regeneration of the cavernous body.

Vascular endothelial growth factors (VEGF) are essential for vasculogenesis and have a potent proangiogenic activity. Among the VEGF family, VEGF-A is the major player in angiogenesis. It is therefore expected that VEGF-A also helps to regenerate the cavernous body by stimulating angiogenesis in the penis. In fact, it was reported that administration of VEGF-A restored erectile function [11]. However, overexpression of VEGF-A causes harmful effects in other organs. In the vascular restenosis model, VEGF-A was expected to stimulate reendothelialization and in

turn inhibit neointimal formation after mechanical injury to the vascular endothelial layer via stimulating migration and proliferation of VECs. Contrary to this expectation, several reports showed that blockade of the endogenous VEGF family rather than stimulation of VEGF-A expression inhibited neointimal formation [12,13]. There are several possible mechanisms by which VEGF-A stimulates neointimal formation. First, VEGF-A stimulates the migration of monocytes/macrophages, because monocytes/macrophages express Flt-1, the type 1 receptor for VEGF [14]. VEGF-A may also stimulate the migration of monocytes/macrophages by increasing the permeability of blood vessels [15]. Second, VEGF-A stimulates the migration and/or proliferation of vascular smooth muscle cell (VSMC)-like cells that reside in the neointimal layer, because these VSMC-like cells reportedly express Flt-1 [12,13]. Thus, some proangiogenic factors such as VEGF-A have proinflammatory activities. It is therefore important to choose an appropriate combination of proangiogenic factors to stimulate regeneration of the cavernous body.

In this study, we examined whether administration of AM and Ang-1 would cooperatively restore erectile function by stimulating regeneration of VECs and VSMCs in the cavernous body. We also compared the effect of coadministration of AM and Ang-1 with that of VEGF-A and/or Ang-1.

## Materials and Methods

### Reagents

Anti-VE-cadherin antibody used for Western blot analysis, anti- $\alpha$ -smooth muscle actin (SMA) antibody, and anti- $\beta$ -actin antibody were purchased from Santa-Cruz Biotechnology Inc. (Santa-Cruz, CA, USA). Anti-VE-cadherin antibody used for immunohistochemical analysis was obtained from LifeSpan BioSciences (Seattle, WA, USA). Anti-type I collagen antibody was purchased from Abcam (Tokyo, Japan).

### Cell Culture

NRK-52E cells, a cell line derived from rat renal tubular cells, and HEK293 cells were obtained from ATCC (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle medium (DMEM) containing 5% fetal bovine serum (FBS).

### Animal Experiments

All procedures involving experimental animals were approved by the institutional committee for

animal research of the Tokyo University. Streptozotocin (STZ; 50 mg/kg body weight; Sigma-Aldrich) was dissolved in citrate buffer (pH 4.5) and injected in the tail vein of male Wistar rats (6 weeks old; Charles River, Wilmington, MA, USA). Blood glucose level was measured 4 weeks later to confirm that these rats had become diabetic. Adenovirus suspension diluted in saline up to 200  $\mu$ L was injected into the penis 6 weeks after STZ injection. Adenovirus expressing green fluorescent protein (AdGFP), adrenomedullin (AdAM), angiotensin-1 (AdAng-1), or vascular endothelial growth factor-A (AdVEGF-A) was injected into the penis (10 rats per group). Furthermore, AdAM plus AdAng-1 or AdVEGF-A plus AdAng-1 was injected into the penis (10 rats per group). Four weeks after adenovirus injection, rats (16 weeks old) were subjected to intracavernous pressure (ICP) measurement. The penis was also harvested for histochemical analysis and Western blot analysis at this time point. The penises isolated from six rats per group were subjected to ICP measurements, and then Western blot analysis. The penises isolated from the remaining four rats per group were used for histochemical analysis. AdGFP-injected diabetic rats were used as negative controls, and age-matched nondiabetic Wistar rats were used as positive controls in this study.

#### ICP Measurement

ICP measurement was performed in the same way as we previously reported [16]. Rats were anesthetized with ketamine (100 mg/kg body weight) injected intraperitoneally. The left carotid artery was exposed and cannulated with a PE-50 polyethylene tube to continuously monitor mean arterial pressure (MAP). The penis was denuded of skin and the pelvic nerve and cavernous nerve were isolated. The right cavernous nerve was hooked with stainless platinum bipolar electrodes (Unique Medical Co., Tokyo, Japan) and connected to a nerve stimulator (Nihon Kohden Co., Tokyo, Japan). Unilateral electrical field stimulation of the cavernous nerve was performed for 10 seconds using a square wave stimulator. The magnitude of the electrical voltage was 5.0 V with a pulse duration of 2 msec, and the frequency of the stimulation was 20 Hz. The right cavernous body was cannulated with a 23-gauge needle connected to a pressure transducer to continuously monitor ICP. Area under the curve (AUC) of ICP traces as well as the ratio of peak ICP to MAP (ICP/MAP) were used to evaluate erectile function. AUC was measured from the point when ICP started to increase from the base line values after

electrical stimulation to the point when ICP decreased and reached a plateau. ICP  $\times$  time was integrated every 0.2 second to calculate AUC.

#### Protein Extraction and Western Blot Analysis

The penis was homogenized in a cell lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40) containing 2  $\mu$ g/mL aprotinin, 2  $\mu$ g/mL leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Western blot analysis was performed as previously described [17]. To detect type I collagen, we performed electrophoresis under nondenatured conditions, because the anti-type I collagen antibody used in this experiment recognizes non-denatured protein. Sodium dodecyl sulfate (SDS) and  $\beta$ -mercaptoethanol were left out from the loading dye, and samples were loaded on polyacrylamide gel without boiling. SDS was also omitted from the polyacrylamide gel, electrophoresis buffer, and transfer buffer. The expression of VE-cadherin, SMA, and type I collagen was normalized by calculating the ratio of the expression of those proteins to that of  $\beta$ -actin.

#### RNA Extraction and Real Time PCR Analysis

Total RNA was extracted using TRIZOL Reagent (Gibco-BRL, Rockville, MD, USA) according to the instructions provided by the manufacturer. To extract total RNA from the rat penis, the penis was homogenized in the TRIZOL Reagent. Total RNA was subjected to reverse transcription using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). Expression of rat AM, Ang-1, VEGF-A and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was examined by real-time PCR using an SYBR Green dye (Thunderbird SYBR qPCR Mix, Toyobo). Primers used were as follows:

RatAMsense, 5'-GCAGTTCCGAAAGAAGTG  
GAAT-3'

RatAMantisense, 5'-GCTGCTGGACGCTTGT  
AGTTC-3'

RatAng-1sense, 5'-CAGGAGGTTGGTGGTT  
TGATG-3'

RatAng-1antisense, 5'-TTTGCCCTGCAGTG  
TAGAACATT-3'

RatVEGF-Asense, 5'-GAGTATATCTTCAAGC  
CGTCCTGTGT-3'

RatVEGF-Aantisense, 5'-TCCAGGGCTTCAT  
CATTGC-3'

RatGAPDHsense, 5'-GTATGACTCTACCCAC  
GGCAAGT-3'

RatGAPDHantisense, 5'-TTCCCGTTGATGA  
CCAGCTT-3'



Real-time PCR was performed using an ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA). To confirm that no significant amounts of primer dimers were formed, dissociation curves were analyzed.

### Histochemistry

The penis was fixed by perfusing it with 4% paraformaldehyde and then processed for paraffin embedding. Cross sections (5  $\mu$ m) were cut, deparaffinized, rehydrated, and subjected to Elastica van Gieson stain to visualize collagen and elastin fibers in the trabeculae of the cavernous body. For immunohistochemistry, sections were incubated with a primary antibody reactive to VE-cadherin and SMA. Sections were then incubated with biotinylated secondary antibody and finally horseradish peroxidase-labeled streptavidin according to the instructions provided by the manufacturer (DAKO, Cambridgeshire, UK).

### Construction of Adenovirus that Expresses VEGF-A

Replication-defective adenovirus that expresses rat VEGF-A was constructed according to the method described previously using an AdMax kit (Microbix Biosystems Inc., Ontario, Canada) [18]. The coding region of rat VEGF-A was amplified by PCR and subcloned into the pDC516 vector. The primer sequences used for PCR were as follows:

RatVEGF-Asense primer: 5'-ATGAACTTTCTGCTCTCTTGGGT-3'

RatVEGF-Aantisense primer: 5'-TCACCGCCTTGGCTTGTCACAT-3'

The result of DNA sequencing analysis showed that the VEGF-A isolated in this study was rat VEGF-A164 corresponding to human VEGF-A165, in which amino acids 141 to 164 were missing by alternative splicing. The expression plasmid pDC516 that expresses rat VEGF-A164 was cotransfected into HEK293 cells with pBHGfrtdelE13FLP to construct an adenovirus expressing rat VEGF-A164 (AdVEGF-A). Construction of adenovirus that expresses rat AM (AdAM) [4] and rat Ang-1 (AdAng-1) [19] has been reported elsewhere. Recombinant adenovirus that expresses GFP (AdGFP) was obtained from Quantum Biotechnologies (Montreal, Canada). These adenoviruses were purified before in vivo use with the Adeno-X Maxi Purification Kit (Takara Bio Inc., Tokyo, Japan) according to the manufacturer's instructions.

### Enzyme-Linked Immunosorbent Assay

Rat VEGF-A in culture medium was measured with an enzyme-linked immunosorbent assay kit (Abcam, Cambridge, UK) according to the methods provided by the manufacturer.


### Statistical Analysis

The values are expressed as the mean  $\pm$  SEM. Statistical analyses were performed using analysis of variance followed by the Student-Neumann-Keuls test. Differences with a *P* value of <0.05 were considered statistically significant.

## Results

### Characterization of AdVEGF-A

We first examined whether AdVEGF-A-infected cells produced VEGF-A using an ELISA kit for rat VEGF-A. We infected NRK-52E cells with AdVEGF-A and measured the VEGF-A content in the culture medium. Although we expected that the NRK-52E cells did not produce endogenous VEGF-A, they produced a significant amount of VEGF-A (Figure 1). However, AdVEGF-A-infected NRK-52E cells produced a more significant amount of VEGF-A (approximately fivefolds) compared with the AdGFP-infected and noninfected control NRK-52E cells, confirming that the AdVEGF-A used in this study produced VEGF-A protein. Previous studies have reported that



**Figure 1** Production of VEGF-A by AdVEGF-A. NRK-52E cells were cultured in 24-well plates and infected with AdGFP or AdVEGF-A for 3 days. After washing the wells with phosphate-buffered saline (PBS), medium was replaced with serum-free DMEM, and incubated for 2 hours. VEGF-A accumulated in the medium was measured with an ELISA kit. Noninfected NRK 52E cells were also used as the control (Control). \*: *P* < 0.001 vs. control and AdGFP infection (*n* = 6 each)


AdAM produces rat AM protein [4] and AdAng-1 produces rat Ang-1 protein [19].

#### Expression of Adenovirus in the Penis

To confirm that adenovirus injected into the penis expressed AM, Ang-1, and VEGF-A in the penis, AdGFP, AdAM, AdAng-1, or AdVEGF-A were injected into the penis of STZ-induced diabetic rats, and the penis was harvested 7 days after adenoviral infection for real-time PCR analysis. Penises injected with AdAM, AdAng-1, and AdVEGF-A expressed significantly higher amounts of AM, Ang-1, and VEGF-A, respectively, than those injected with AdGFP. This result suggested that adenovirus injected into the penis remained and those cytokines were therefore expressed (Figure 2).


#### Effects of Administration of AdAM, AdAng-1, and AdVEGF-A on ICP

We infected AdAM, AdAng-1, and AdVEGF-A into the cavernous body at the glans of STZ-induced diabetic rats and measured ICP 4 weeks after the infection. We confirmed in a previous study that AdGFP infection did not affect ICP or histology in STZ-induced diabetic rats [4]. We analyzed not only ICP and AUC of ICP traces, but also  $T_{max}$  and  $T_{1/2}$ .  $T_{max}$  is defined as a period from when ICP starts to increase after electrical stimulation to when ICP reaches maximal level (Figure 3A).  $T_{1/2}$  is defined as a period from when ICP starts to increase after electrical stimulation to when ICP decreases to the 50% level of its maximal value (Figure 3A). Infection of the penis with AdAM, AdAng1, AdAM plus AdAng-1, AdVEGF-A, and AdVEGF-A plus AdAng-1 all restored ICP significantly compared with AdGFP infection in the diabetic rats (Figure 3B). Infection with AdAM plus AdAng-1, AdVEGF-A, and AdVEGF-A plus AdAng-1 restored ICP to a level similar to that observed in age-matched Wistar rats (positive control). Infection with AdAM, AdAng1, AdAM plus AdAng-1, AdVEGF-A, and AdVEGF-A plus AdAng-1 also increased AUC of the ICP traces significantly compared with AdGFP infection in the diabetic rats (Figure 3C). Infection with AdAM plus AdAng-1 restored AUC most significantly.  $T_{max}$  in the AdGFP-infected group was significantly elongated compared with the positive control group (Figure 3D), and  $T_{max}$  in the AdAng-1-infected group tended to be retarded, and there was no significant difference in  $T_{max}$  between the AdGFP-infected group and the AdAng-1-infected group. These results suggested



**Figure 2** Expression of adenovirus in the penis. AdAM, AdAng-1, or AdVEGF-A was injected into the penis of STZ-induced diabetic rats, and the penis was isolated 7 days after adenoviral injection for real-time PCR analysis. AdGFP was also injected into the penis as a negative control. Expression of AM, Ang-1, and VEGF-A (VEGF) was normalized by that of GAPDH ( $n=4$  each). \*:  $P < 0.01$  vs. AdGFP infection

that blood filling into the cavernous body occurred more slowly in the AdGFP-infected and AdAng-1-infected diabetic rats than the age-matched Wistar rats. Interestingly,  $T_{max}$  in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups was significantly shortened compared with the positive control group, suggesting that blood filling into the cavernous body occurred faster in these groups than the positive control.  $T_{max}$  in the AdAM- and AdAM plus AdAng-1-infected groups was similar to that in the positive control group.  $T_{1/2}$  in the AdGFP- and AdAng-1-infected groups was significantly elongated compared with the positive control (Figure 3E).  $T_{1/2}$  in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups was significantly shortened




**Figure 3** Effects of AdAM, AdAng-1, and AdVEGF-A infection on erectile function. These adenoviruses were infected into the cavernous body of STZ-induced diabetic rats. Age-matched Wistar rats were used as the positive control (PC). (A) Schematic representation of ICP traces. The dashed box indicates the timing and duration of electrical stimulation. The dotted area represents AUC. Tmax was defined as the period from when ICP started to rise to when ICP reached its peak level.  $T_{1/2}$  was defined as the period from when ICP started to rise to when it fell to the 50% of its peak level. (B) Bar graphs comparing ICP/MAP among the groups ( $n = 6$  each). \*:  $P < 0.001$  vs. AdGFP infection and †:  $P < 0.001$  vs. PC. (C) Bar graphs comparing AUC/MAP among the groups ( $n = 6$  each). \*:  $P < 0.001$  vs. AdGFP infection, and † and ††:  $P < 0.01$  and  $P < 0.001$ , respectively, vs. PC. (D) Bar graphs comparing Tmax among the groups ( $n = 6$  each). \*:  $P < 0.001$  vs. AdGFP infection and † and ††:  $P < 0.05$  and  $P < 0.001$ , respectively vs. PC. (E) Bar graphs comparing  $T_{1/2}$  among the groups ( $n = 6$  each). \*:  $P < 0.001$  vs. AdGFP infection and †:  $P < 0.001$  vs. PC

compared with the positive control group.  $T_{1/2}$  in the AdAM- and AdAM plus AdAng-1-infected groups was similar to that in the positive control group. Collectively, infection with AdAM, AdAng1, AdAM plus AdAng-1, AdVEGF-A, and AdVEGF-A plus AdAng-1 all restored erectile function significantly. The effect of AdAM plus AdAng-1 infection was most significant, and the erectile function in this group was similar to that in the positive control group. The speed of rise and fall of ICP after electrical stimulation was decreased in the AdGFP- and AdAng-1-infected groups compared with the positive control group. The speed increased in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups compared with the positive control group. The speed did not change significantly in the AdAM- or

AdAM plus AdAng-1-infected group compared with the positive control group. Thus, ICP traces in the AdAM plus AdAng-1-infected group mostly mimicked those in the positive control group.

#### Effects of Administration of AdAM, AdAng-1, and AdVEGF-A on Histology of the Cavernous Body

To examine the mechanisms by which these adenoviral infections restored erectile function, we examined the morphology of the cavernous body by Elastica van Gieson staining. The trabeculae of the cavernous body at the root of the penis in the AdGFP-infected diabetic rats were smaller than those in the positive control Wistar rats (Figure 4). Infection with AdAM and/or AdAng-1 restored the size of the trabeculae of the cavernous body.




**Figure 4** Histological analysis of the cavernous body after adenoviral infection. Elastic van Gieson staining of the cavernous body isolated from age-matched Wistar rats (PC), and STZ-induced diabetic rats infected with AdGFP, AdAM, AdAng-1, AdAM plus AdAng-1, AdVEGF-A (AdVEGF), and AdVEGF-A plus AdAng-1. The histology of the root portion of the penis (longitudinal section) is shown. Bars are 300  $\mu$ m.


Interestingly, the trabeculae of the cavernous body were rather enlarged and densely distributed in the cavernous body in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups compared with the positive control group. We next examined the distribution of SMA and VE-cadherin by immunohistological analysis. The SMA layer around the trabeculae of the cavernous body in the AdGFP-infected diabetic rats looked thinner than that in the other adenovirus-infected groups and the positive control group (Figure 5). The VE-cadherin-positive endothelial layer around the trabeculae of the cavernous body was observed in all groups (Figure 6), and the ratios of trabeculae covered with VECs to those uncovered with VECs seemed to be similar among the groups, although the total amount of the endothelial layer might be different among the groups because the size and the density of the trabeculae of the cavernous body differed among the groups. Interestingly, we observed a VE-cadherin-positive tube-like structure in the trabeculae of the cavernous body in the AdVEGF-A-infected group (Figure 6), suggesting that an aberrant angiogenesis occurred in the AdVEGF-A-infected group.

*Effects of Administration of AdAM, AdAng-1, and AdVEGF-A on the Expression of VE-Cadherin, SMA, and Type I Collagen*


To quantify the expression of SMA and VE-cadherin, we performed Western blot analysis (Figure 7). Infection with AdAM or AdAng-1 increased SMA expression slightly but significantly compared with AdGFP infection. Infection with AdAM plus AdAng-1, AdVEGF-A, and AdVEGF-A plus AdAng-1 increased SMA expression more significantly, and the expression level was similar to that in the age-matched positive control group. Infection with AdAM or AdAng-1 significantly increased VE-cadherin expression compared with AdGFP infection. Infection with AdAM plus AdAng-1 increased VE-cadherin expression more significantly, and the expression reached a level similar to that in the positive control group. The expression of VE-cadherin in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups rather surpassed the expression level observed in the positive control. We also examined the expression of type I collagen as a marker to quantify the content of collagen fibers in the trabeculae of the cavernous body, because we found that the trabeculae were “hypertrophied” in



**Figure 5** Immunohistochemical analysis of the cavernous body isolated from age-matched Wistar rats (PC) and STZ-induced diabetic rats infected with AdGFP, AdAM, AdAng-1, AdAM plus AdAng-1, AdVEGF-A (AdVEGF), and AdVEGF-A plus AdAng-1. SMA was stained to visualize the smooth muscle layer in the cavernous body. The longitudinal section of the cavernous body at the root of the penis is shown. Bars are 300  $\mu$ m.



**Figure 6** Immunohistochemical analysis of the cavernous body isolated from age-matched Wistar rats (PC) and STZ-induced diabetic rats infected with AdGFP, AdAM, AdAng-1, AdAM plus AdAng-1, AdVEGF-A (AdVEGF), and AdVEGF-A plus AdAng-1. VE-cadherin was stained to visualize the endothelial layer in the cavernous body. Area of aberrant angiogenesis observed in the trabeculae of the cavernous body of AdVEGF-A infected penis was boxed and enlarged in the white box. The longitudinal section of the cavernous body at the root of the penis is shown. Bars are 100  $\mu$ m.



**Figure 7** Western blot analysis of the expressions of SMA, VE-cadherin, and type I collagen in the penis. (A) AdGFP, AdAM, AdAng-1, AdAM plus AdAng-1, AdVEGF-A (AdVEGF), and AdVEGF-A plus AdAng-1 were infected in the cavernous body of STZ-treated diabetic rats, and the penis was isolated for protein extraction 4 weeks after adenoviral injection. Age-matched Wistar rats were used as the positive control (PC). The blotted membranes were incubated with anti-SMA antibody, anti-VE-cadherin antibody, and then anti-β-actin antibody as the internal control. To detect type I collagen, protein extracts were electrophoresed on nondenatured SDS polyacrylamide gels, and blotted membranes were incubated with anti-type I collagen antibody and then anti-β-actin antibody as the internal control. (B) Histograms showing relative intensity of the bands ( $n = 4$  each). \* and \*\*:  $P < 0.05$  and  $P < 0.01$  vs. AdGFP infection, and † and ††:  $P < 0.05$  and  $P < 0.01$ , respectively, vs. PC.

the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups. Expression level of type I collagen in the AdGFP-infected diabetic rats was significantly lower than that in the positive control. AdAM and/or AdAng-1 infection significantly restored the expression of type I collagen to a level similar to that in the positive control. Infection with AdVEGF-A and AdVEGF-A plus AdAng-1 further increased the expression of type I collagen, and the expression level significantly exceeded that in the positive control. Collectively, these results suggested that the vascular networks of the cavernous sinus were poorly developed in the AdGFP-infected diabetic rats, and infection with AdAM, AdAng-1, and AdVEGF-A restored the networks significantly. However, AdVEGF-A infection induced an excess amount of angiogenesis and synthesis of collagen fibers, resulting in aberrant angiogenesis in the trabeculae of the cavernous body and “hypertrophy” of the trabeculae.

#### Blood Glucose Levels Before and After Adenoviral Infection

To confirm that adenoviral infection did not affect blood glucose levels, we measured the casual blood glucose levels 4 weeks after STZ injection (before adenoviral infection) and 10 weeks after STZ injection (4 weeks after adenoviral infection). Adenoviral infection did not significantly alter the blood glucose levels, and the diabetic rats remained diabetic after the infection. The blood glucose levels of adenovirus-infected diabetic rats were significantly higher than age-matched non-diabetic rats (16 weeks old) (Supporting Information Figure S1).

## Discussion

In this study, we found that overexpression of AM, Ang-1, and VEGF-A by adenoviral infection significantly restored erectile function in terms of ICP, histology of the penis, and expression of several proteins in the penis. Among several combinations, infection with AdAM plus AdAng-1 mostly mimicked the erectile function in the age-matched positive control. AdAM plus AdAng-1 infection restored ICP and AUC of the ICP traces to a similar level observed in the positive control. The pattern of the increase and decrease of ICP after electrical stimulation was similar between the AdAM plus AdAng-1-infected group and the positive control group. Expression of SMA and VE-cadherin was also similar between the AdAM plus AdAng-1-infected group and the positive control group. In contrast, although ICP rose sufficiently after electrical stimulation in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups, the rise and fall of ICP occurred more rapidly, as assessed by  $T_{max}$  and  $T_{1/2}$ , resulting in a smaller value of AUC compared with the AdAM plus AdAng-1-infected group and the positive control. Infection with AdVEGF-A and AdVEGF-A plus AdAng-1 induced "hypertrophy" of the trabeculae of the cavernous body and overproduction of collagen fibers in the trabeculae. Infection with AdVEGF-A induced aberrant angiogenesis in the trabeculae. We propose the following scenario about the effect of AdVEGF-A- and AdVEGF-A plus AdAng-1-infection. Because the trabeculae of the cavernous body were "hypertrophied," the area of the cavernous sinus was relatively small in these rats. Therefore, once erection started, blood filled in the cavernous sinus rapidly, but once erection ceased, blood outflow from the cavernous sinus also occurred rapidly. That is why the level of ICP rose and fell rapidly in the AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups. Another possibility is that AdVEGF-A infection did not sufficiently improve corporal veno-occlusive dysfunction (CVOD). It is well known that CVOD is the most prevalent cause of ED. This disorder results from an inadequate relaxation of the corporal smooth muscle, resulting in insufficient compression of the subtunical veins against the tunica albuginea [20]. Decreases in the amount of smooth muscle cells (SMC) and/or increases in the amount of collagen in the cavernous body appear to result in dysfunction of the corporal smooth muscle and CVOD [21,22]. Infection with AdAM plus AdAng-1

restored the amount of SMC in the cavernous body without increases in the amount of collagen fibers, whereas infection with AdVEGF-A and AdVEGF-A plus AdAng-1 increased the amount of collagen as well as SMC. This may be the reason why the blood flowed out of the cavernous body rapidly after cessation of electrical stimulation in AdVEGF-A- and AdVEGF-A plus AdAng-1-infected groups compared with the AdAM plus AdAng-1-infected group.

Although VEGF are essential for vasculogenesis and have probably the most potent proangiogenic activity, overproduction of VEGF potentially causes a harmful effect on organ physiology [12,13]. In fact, it was reported that the VEGF-A gene transfer using the adeno-associated virus into rabbit ischemic hind limb skeletal muscles caused aberrant angiogenesis and fibrosis in skeletal muscles [23]. It was also reported that the blockade of the type 2 receptor for the VEGF family resulted in attenuation of fibrosis in the kidney in a unilateral ureteric obstruction model [24]. Therefore, it appears that an appropriate amount of VEGF-A is necessary for physiological angiogenesis and that overproduction of VEGF-A potentially causes aberrant angiogenesis, inflammation, and fibrosis.

Ang-1 reportedly restored erectile function in a diabetes model and a hyperlipidemia model [11,25]. In addition to proangiogenic activity, Ang-1 appears to have an inhibitory effect on fibrosis. It was shown that a variant of Ang-1 (cartilage oligomeric matrix protein-Ang-1) that is stable and has a potent activity, inhibited fibrosis in a unilateral ureteric obstruction model of the kidney [26]. Furthermore, Ang-1 reportedly inhibits tissue inflammation via suppression of macrophage infiltration and activation [27,28]. Thus, it seems to be reasonable to use Ang-1 for the treatment of ED.

AM was originally isolated from human pheochromocytoma tissue and has potent natriuretic, vasorelaxant, and proangiogenic activities [5–8]. We have shown that overproduction of AM in the penis restores erectile function via stimulation of the regeneration of the cavernous tissue and via restoration of endothelial function [4]. Furthermore, it was reported that AM inhibited tissue fibrosis in the heart and the kidney [29–31]. Thus, AM also has proangiogenic and antifibrotic activities like Ang-1. In this study, we found that infection with AdAM plus AdAng-1 in the penis restored erectile function more potently than infection with AdAM alone or AdAng-1 alone.

Expression of SMA and VE-cadherin in the penis increased more significantly in the AdAM plus AdAng-1-infected group than in the AdAM-infected and AdAng-1-infected group without overproduction of type I collagen. The expressions of SMA and VE-cadherin in the AdAM plus AdAng-1-infected group increased to a level similar to that observed in the positive control group. Thus, vascular networks in the cavernous sinus appear to be restored more significantly by AdAM plus AdAng-1-infection than by AdAM infection alone or AdAng-1 infection alone. This can be a mechanism whereby AM and Ang-1 additively restore erectile function. Another possible mechanism is that AM and Ang-1 additively restored vascular endothelial function. In fact, we have reported that AM stimulates phosphorylation and activation of endothelial nitric oxide synthase (eNOS) in the penis [4]. Another study reported that Ang-1 stimulates phosphorylation of eNOS in the penis [11]. Furthermore, AM and Ang-1 reportedly inhibit the production of reactive oxygen species (ROS) [32,33]. As it has been shown that ROS are implicated in ED in diabetes [34,35], AM and Ang-1 may restore erectile function via suppression of ROS production. Therefore, it is possible that AM and Ang-1 additively restores erectile function via improvement of vascular endothelial function by activating eNOS and/or suppressing ROS production in an additive manner. Future studies are required to elucidate these possibilities.

#### Limitations of This Study

Adenovirus was injected into the penis. Thus, some portions of the injected adenovirus may have entered the systemic circulation and got trapped in the tissues of organs such as the liver, which may then have produced AM, Ang-1, or VEGF-A. These cytokines produced outside the penis may have entered the systemic circulation and affected the results of this study. However, we believe that this effect was minimal, if present at all, because no decline in blood pressure was observed after injection of AdAM into the penis (data not shown). Because AM has a potent vasodilator activity, blood pressure should have decreased if systemically delivered adenovirus played a major role in erectile function.

AM, Ang-1, and/or VEGF-A may have also improved erectile function through regenerative effects on the autonomic nervous system. This possibility should be addressed in a future study.

#### Conclusions

Combination therapy with AM and Ang-1 additively restored erectile function to a level very similar to that observed in the age-matched Wistar rats. This combination therapy effectively regenerated vascular structure in the cavernous body without inducing aberrant angiogenesis, overproduction of collagens and "hypertrophy" of the trabeculae of the cavernous body. This combination therapy will be useful to treat ED resulting from old age and diabetes.

#### Acknowledgment

This study was supported in part by Grants-in-Aid #21592066 and #24592423 (to H. N.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

**Corresponding Author:** Etsu Suzuki, MD, PhD, Institute of Medical Science, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8512, Japan. Tel: +81-44-977-8111; Fax: +81-44-977-8361; E-mail: esuzuki-tky@umin.ac.jp

*Conflict of Interest:* The author(s) report no conflicts of interest.

#### Statement of Authorship

##### Category 1

##### (a) Conception and Design

Etsu Suzuki; Hiroaki Nishimatsu; Yukio Homma

##### (b) Acquisition of Data

Etsu Suzuki; Hiroaki Nishimatsu; Akira Nomiya; Aya Niimi; Motofumi Suzuki; Tetsuya Fujimura; Hiroshi Fukuhara

##### (c) Analysis and Interpretation of Data

Etsu Suzuki; Hiroaki Nishimatsu; Akira Nomiya; Aya Niimi

##### Category 2

##### (a) Drafting the Article

Etsu Suzuki; Hiroaki Nishimatsu; Yukio Homma

##### (b) Revising It for Intellectual Content

Akira Nomiya; Aya Niimi; Motofumi Suzuki; Tetsuya Fujimura; Hiroshi Fukuhara

##### Category 3

##### (a) Final approval of the completed article

Etsu Suzuki; Hiroaki Nishimatsu; Akira Nomiya; Aya Niimi; Motofumi Suzuki; Tetsuya Fujimura; Hiroshi Fukuhara; Yukio Homma

#### References

- 1 Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. *J Sex Med* 2009;6:1232-47.



- 2 Dey J, Shepherd MD. Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. *Mayo Clin Proc* 2002;77:276–82.
- 3 Siroky MB, Azadzi KM. Vasculogenic erectile dysfunction: Newer therapeutic strategies. *J Urol* 2003;170:S24–30.
- 4 Nishimatsu H, Suzuki E, Kumano S, Nomiya A, Liu M, Kume H, Homma Y. Adrenomedullin mediates adipose tissue-derived stem cell-induced restoration of erectile function in diabetic rats. *J Sex Med* 2012;9:482–93.
- 5 Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. *Biochem Biophys Res Commun* 1993;192:553–60.
- 6 Kim W, Moon SO, Sung MJ, Kim SH, Lee S, So JN, Park SK. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. *FASEB J* 2003;17:1937–9.
- 7 Tokunaga N, Nagaya N, Shirai M, Tanaka E, Ishibashi-Ueda H, Harada-Shiba M, Kanda M, Ito T, Shimizu W, Tabata Y, Uematsu M, Nishigami K, Sano S, Kangawa K, Mori H. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: Benefits of a novel nonviral vector, gelatin. *Circulation* 2004;109:526–31.
- 8 Iimuro S, Shindo T, Moriyama N, Amaki T, Niu P, Takeda N, Iwata H, Zhang Y, Ebihara A, Nagai R. Angiogenic effects of adrenomedullin in ischemia and tumor growth. *Circ Res* 2004;95:415–23.
- 9 Takahashi M, Suzuki E, Oba S, Nishimatsu H, Kimura K, Nagano T, Nagai R, Hirata Y. Adipose tissue-derived stem cells inhibit neointimal formation in a paracrine fashion in rat femoral artery. *Am J Physiol Heart Circ Physiol* 2010;298:H415–23.
- 10 Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the tie2 receptor, by secretion-trap expression cloning. *Cell* 1996;87:1161–9.
- 11 Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M, Piao S, Han JY, Kim IH, Koh GY, Suh JK. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. *Mol Ther* 2006;13:705–15.
- 12 Zhao Q, Egashira K, Hiasa K, Ishibashi M, Inoue S, Ohtani K, Tan C, Shibuya M, Takeshita A, Sunagawa K. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. *Arterioscler Thromb Vasc Biol* 2004;24:2284–9.
- 13 Ohtani K, Egashira K, Hiasa K, Zhao Q, Kitamoto S, Ishibashi M, Usui M, Inoue S, Yonemitsu Y, Sueishi K, Sata M, Shibuya M, Sunagawa K. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. *Circulation* 2004;110:2444–52.
- 14 Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. *Blood* 2001;97:785–91.
- 15 Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. *Cell Struct Funct* 2001;26:25–35.
- 16 Nishimatsu H, Hirata Y, Hayakawa H, Nagata D, Satonaka H, Suzuki E, Horie S, Takeuchi T, Ohta N, Homma Y, Minowada S, Nagai R, Kawabe K, Kitamura T. Effects of intracavernous administration of adrenomedullin on erectile function in rats. *Peptides* 2001;22:1913–8.
- 17 Suzuki E, Nagata D, Yoshizumi M, Kakoki M, Goto A, Omata M, Hirata Y. Reentry into the cell cycle of contact-inhibited vascular endothelial cells by a phosphatase inhibitor: Possible involvement of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. *J Biol Chem* 2000;275:3637–44.
- 18 Suzuki E, Nishimatsu H, Satonaka H, Walsh K, Goto A, Omata M, Fujita T, Nagai R, Hirata Y. Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes. *Circ Res* 2002;90:1004–11.
- 19 Takahashi M, Suzuki E, Kumano S, Oba S, Sato T, Nishimatsu H, Kimura K, Nagano T, Hirata Y. Angiotensin II mediates adipose tissue-derived stem cell-induced inhibition of neointimal formation in rat femoral artery. *Circ J* 14 Mar 2013 [Epub ahead of print] doi: 10.1253/circj.CJ-12-0930.
- 20 Wespes E, Sattar AA, Golzarian J, Wery D, Daoud N, Schulman CC. Corporal veno-occlusive dysfunction: Predominantly intracavernous muscular pathology. *J Urol* 1997;157:1678–80.
- 21 Garban H, Marquez D, Cai L, Rajfer J, Gonzalez-Cadavid NF. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. *Biol Reprod* 1995;53:1365–72.
- 22 Bakircioglu ME, Sievert KD, Nunes L, Lau A, Lin CS, Lue TF. Decreased trabecular smooth muscle and caveolin-1 expression in the penile tissue of aged rats. *J Urol* 2001;166:734–8.
- 23 Karvinen H, Pasanen E, Rissanen TT, Korpisalo P, Vahakangas E, Jazwa A, Giacca M, Yla-Herttuala S. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. *Gene Ther* 2011;18:1166–72.
- 24 Lin SL, Chang FC, Schrimpf C, Chen YT, Wu CF, Wu VC, Chiang WC, Kuhnert F, Kuo CJ, Chen YM, Wu KD, Tsai TJ, Duffield JS. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. *Am J Pathol* 2011;178:911–23.
- 25 Jin HR, Kim WJ, Song JS, Piao S, Choi MJ, Tumurbaatar M, Shin SH, Yin GN, Koh GY, Ryu JK, Suh JK. Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. *Diabetes* 2011;60:969–80.
- 26 Kim W, Moon SO, Lee SY, Jang KY, Cho CH, Koh GY, Choi KS, Yoon KH, Sung MJ, Kim DH, Lee S, Kang KP, Park SK. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. *J Am Soc Nephrol* 2006;17:2474–83.
- 27 Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. *Circ Res* 2001;89:477–9.
- 28 Gu H, Cui M, Bai Y, Chen F, Ma K, Zhou C, Guo L. Angiopoietin-1/Tie2 signaling pathway inhibits lipopolysaccharide-induced activation of raw264.7 macrophage cells. *Biochem Biophys Res Commun* 2010;392:178–82.
- 29 Zhang JJ, Yoshida H, Chao L, Chao J. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive Dahl salt-sensitive rats. *Hum Gene Ther* 2000;11:1817–27.
- 30 Niu P, Shindo T, Iwata H, Iimuro S, Takeda N, Zhang Y, Ebihara A, Suematsu Y, Kangawa K, Hirata Y, Nagai R. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. *Circulation* 2004;109:1789–94.
- 31 Nagae T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Saito Y, Ogawa Y, Kuwabara T, Tanaka I, Sugawara A, Kuwahara T, Nakao K. Adrenomedullin inhibits connective tissue growth factor expression, extracellular signal-regulated kinase activation and renal fibrosis. *Kidney Int* 2008;74:70–80.

- 32 Ismail NS, Pravda EA, Li D, Shih SC, Dallabrida SM. Angiotensin-1 reduces h(2)o(2)-induced increases in reactive oxygen species and oxidative damage to skin cells. *J Invest Dermatol* 2010;130:1307–17.
- 33 Kim SM, Kim JY, Lee S, Park JH. Adrenomedullin protects against hypoxia/reoxygenation-induced cell death by suppression of reactive oxygen species via thiol redox systems. *FEBS Lett* 2010;584:213–8.
- 34 Long T, Liu G, Wang Y, Chen Y, Zhang Y, Qin D. TNF-alpha, erectile dysfunction, and NADPH oxidase-mediated ros generation in corpus cavernosum in high-fat diet/streptozotocin-induced diabetic rats. *J Sex Med* 2012;9:1801–14.
- 35 Li M, Zhuan L, Wang T, Rao K, Yang J, Quan W, Liu J, Ye Z. Apocynin improves erectile function in diabetic rats through

regulation of NADPH oxidase expression. *J Sex Med* 2012;9:3041–50.

### Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

**Figure S1** Blood glucose levels before and after adenoviral infection. Casual blood glucose levels were measured in each group 4 weeks after STZ injection (before adenoviral injection; white boxes) and 10 weeks after STZ injection (4 weeks after adenoviral injection; black boxes). Casual blood glucose levels were also measured in age-matched positive control rats (PC; dotted box). †:  $P < 0.05$  vs. positive control rats.  $N = 6$  in each group.

**Original Article: Laboratory Investigation****Reduction of prostate cancer incidence by naftopidil, an  $\alpha_1$ -adrenoceptor antagonist and transforming growth factor- $\beta$  signaling inhibitor**Daisuke Yamada,<sup>1,2</sup> Hiroaki Nishimatsu,<sup>1</sup> Shintaro Kumano,<sup>1</sup> Yoshikazu Hirano,<sup>2</sup> Motofumi Suzuki,<sup>1</sup> Tetsuya Fujimura,<sup>1</sup> Hiroshi Fukuhara,<sup>1</sup> Yutaka Enomoto,<sup>1</sup> Haruki Kume<sup>1</sup> and Yukio Homma<sup>1</sup><sup>1</sup>Department of Urology, The University of Tokyo Hospital, and <sup>2</sup>Department of Urology, The Fraternity Memorial Hospital, Tokyo, Japan**Abbreviations & Acronyms**

BPH = benign prostatic hyperplasia  
BSA = bovine serum albumin  
DAPI = diamidino-2-phenylindole  
DMSO = dimethylsulfoxide  
IC<sub>50</sub> = half maximal inhibitory concentration  
PC = prostate cancer  
PSA = prostate-specific antigen  
R1 = receptor 1  
RT = room temperature  
TGF- $\beta$  = transforming growth factor- $\beta$   
TUNEL = terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling  
TUR-P = transurethral resection of the prostate

**Objectives:** Quinazoline-based  $\alpha_1$ -adrenoceptor antagonists are known to inhibit prostate tumor growth through induction of apoptosis. We investigated the effect of a naphthalene-based  $\alpha_1$ -adrenoceptor antagonist, naftopidil, on prostate cancer incidence, apoptosis of prostatic cell and transforming growth factor- $\beta$  signaling.

**Methods:** Prescription records were linked to pathological data for men who continued naftopidil ( $n = 766$ ) or tamsulosin ( $n = 1015$ ) for 3 months or longer between 2003 and 2010. Prostate cancer incidence was analyzed by log-rank test and the Cox proportional hazards model. Apoptosis and cell cycle arrest in human tissues were assessed by immunohistochemical detection of Bcl2 and p21, respectively. Growth inhibition and apoptosis treatment with naftopidil and tamsulosin were assessed in cancer cell lines. Interference with transforming growth factor- $\beta$  signaling was examined by western blot analysis.

**Results:** Prostate cancer incidence was significantly lower in men who received naftopidil for 3 months or longer compared with tamsulosin ( $P = 0.035$ ). Multivariate analysis confirmed a decreased hazard ratio, 0.46, for naftopidil use ( $P = 0.013$ ), which was more evident with longer treatment. Immunohistochemical positivity for Bcl2, a marker for resistance to apoptosis, was less frequently detected in prostate cancer cells of men who received naftopidil compared with tamsulosin ( $P < 0.05$ ). Naftopidil inhibited cancer cell growth, induced apoptosis and blocked Smad2 phosphorylation activated by transforming growth factor- $\beta$  in cell lines, with a half maximal inhibitory concentration of 1.1  $\mu\text{mol/L}$ .

**Conclusions:** Naftopidil seems to reduce prostate cancer incidence, possibly by inducing apoptosis, preferentially in cancer cells, and blocking transforming growth factor- $\beta$  signaling.

**Key words:** adrenoceptor, incidence, naftopidil, prostate cancer, transforming growth factor.

**Correspondence:** Hiroaki Nishimatsu M.D., Ph.D., Department of Urology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Email: nishimatsu-tky@umin.ac.jp

Received 10 August 2012;  
accepted 6 March 2013.  
Online publication 21 April 2013

**Introduction**


Some  $\alpha_1$ -adrenoceptor antagonists, such as doxazosin and terazosin, can reduce PC incidence, whereas other  $\alpha_1$ -adrenoceptor antagonists; that is, tamsulosin, cannot.<sup>1–5</sup> This inhibitory effect is reportedly mediated by apoptosis induction, and independent from the property of  $\alpha_1$ -adrenoceptor antagonist; overexpression of  $\alpha_1$  adrenoceptor did not influence apoptosis and cell viability;<sup>1</sup> exposure to phenoxybenzamine, an irreversible inhibitor of  $\alpha_1$ -adrenoceptors, failed to prevent the apoptotic effect of doxazosin.<sup>3</sup> G1 cell cycle arrest has been implicated in the growth inhibitory property of naftopidil, another  $\alpha_1$ -adrenoceptor, in human PC cell lines.<sup>6</sup>

In the present study, we investigated the effects of naftopidil on PC incidence in an observational cohort and the possible role of TGF- $\beta$  signaling in its inhibition mechanism.

**Table 1** Backgrounds in men treated with naftopidil or tamsulosin for 3 months or longer

	3 Months or longer			12 Months or longer			36 Months or longer		
	Naftopidil (n = 766)	Tamsulosin (n = 1015)	P-value	Naftopidil (n = 433)	Tamsulosin (n = 506)	P-value	Naftopidil (n = 203)	Tamsulosin (n = 208)	P-value
Baseline age (years)	71 (64–76)†	71 (65–78)	0.09	71 (64–76)	72 (66–78)	0.10	71 (64–76)	72 (66–79)	0.12
Baseline PSA level (ng/mL)	2.5 (1.1–4.9)†	2.3 (1.0–4.6)	0.14	2.5 (1.2–4.9)	2.3 (1.0–4.4)	0.09	2.3 (1.1–4.5)	2.1 (1.1–3.9)	0.27
Methods for examination of the prostate									
Biopsy	197 (25)‡	250 (24)	0.60	124 (29)	134 (26)	0.46	64 (32)	56 (27)	0.30
TUR-P	93 (12)‡	120 (11)	0.83	49 (11)	67 (13)	0.37	12 (6)	21 (10)	0.11
Either	239 (31)‡	313 (30)	0.86	147 (34)	169 (33)	0.85	68 (33)	69 (33)	0.94

†Median (quartile range). ‡Cases (%).

**Fig. 1** Cumulative PC incidence in men during treatment with  $\alpha_1$ -adrenoceptor antagonists. (a) There was no significant difference between men aged 71 years or older (—) and men aged less than 71 years (---). (b) The incidence was higher in men with PSA  $\geq 4.0$  ng/mL (—) than in men with PSA  $< 4.0$  ng/mL (---;  $P < 0.001$ ). (c) It was lower in men receiving naftopidil (—) than in men receiving tamsulosin (---;  $P = 0.035$ ).

## Methods

A retrospective observational cohort study was carried out on men who received naftopidil or tamsulosin at the Fraternity Memorial Hospital in Tokyo, Japan, between 2003 and 2010. Medications, including  $\alpha_1$ -adrenoceptor antagonists and hormonal agents, were listed from prescription records of the pharmacy. Patient data, including pathological results, were linked by the identification number. Men receiving hormonal therapy or diagnosed with PC before treatment with  $\alpha_1$ -adrenoceptors were excluded. All the men had PSA checked before starting medication. The time zero of the present study was the time treatment with  $\alpha_1$ -adrenoceptor antagonists was started. The end-points of follow up were stopping of the  $\alpha_1$ -adrenoceptor antagonist or starting hormonal therapy (censored), or diagnosis of PC (evented). The follow up ended in December 2010 in patients who continued the same  $\alpha_1$ -adrenoceptor antagonists without diagnosis of PC.

The decision to carry out prostate biopsy or TUR-P was made clinically by the primary physicians. Men with follow up less than 3 months were excluded because of minimal exposure to the agents.

## Immunohistochemistry

We used fresh prostatic tissues obtained from men with or without PC who received naftopidil, tamsulosin or neither ( $n = 10$ , each). The specimens were fixed in formalin, dehydrated, embedded in paraffin and cut into 3- $\mu$ m sections using a Yamato large-scale microtome (TU213; Yamatokohki, Saitama, Japan). After deparaffinization, the sections were hydrated and incubated for 10 min in 3% hydrogen peroxide in methanol. Sections were heated in a steel pressure oven in 10 mmol/L citrate buffer, pH 6.0, to 120°C for 20 min. Non-specific binding was blocked using 2% normal goat blocking serum (X0907; Dako Cytomation, Glostrup, Denmark). Primary and secondary antibodies were incubated for 1 h and 0.5 h at RT, respectively. After washing, sections were incubated with EnVision (K4063; Dako Cytomation) at RT for 1 h, visualized with 3,3'-diaminobenzidine and stained with hematoxylin. The primary antibodies used were anti-p21 (#2947; Cell Signaling Technology, Danvers, MA, USA) and anti-Bcl2 (M0887; Dako Cytomation), both diluted 1:50. To confirm specificity of staining, primary antibodies were mixed with p21 (#1055; Cell Signaling Technology) and Bcl2